Два случаја на несиндромска конгенитална унилатерална хипоплазија во една фамилија

Micromastia or breast hypoplasia is described as underdevelopment of a woman's mammary tissue. We present the case of a 15-year-old girl with unilateral micromastia, with familial predisposition. Ultrasound, hormonal, dysmorphic, cardiologic, genetic examinations and testing were performed. No mutation in the whole- exome sequencing was found, nor novel mutation. Some of these cases have been reported to be related to breаst cancer so further follow-up is mandatory. Therapy consists of surgical reconstruction of the affected breast. This is a rare condition and it requires a multidisciplinary approach.Микромастија или хипоплазија на дојки е опишана како недоразвиеност на ткивото на дојката кај жените. Опишавме случај на 15-годишно девојче со унилатерална микромастија со фамилијарна предиспозиција. Беа направени ехосонографски, хормонални, дисморфични, кардиолошки и генетски испитувања и тестови. Не беше пронајдена мутација на целокупниот секвенциониран ексом, ниту пак нова мутација. Некои од овие случаи се прикажани како да се поврзани со канцер на дојката и затоа се потребни понатамошни задолжителни следења. Терапијата се состои од хируршка реконструкција на афектираната дојка. Ова претставува ретка состојба, но бара мултидисциплинарен пристап

Growing Prevalence and Incidence of Diabetes in Republic of Macedonia in the Past 5 Years Based on Data from the National System for Electronic Health Records

Introduction. Diabetes is a chronic metabolic disease characterized with a rapid progression of prevalence in last 3 decades, especially in countries with low and middle income. Next three decades this number of diabetes in the world is expected to be doubled. Early diagnosis and appropriate management of diabetes is the primary way to prevent and delay cardiovascular complications. Patients and methods. In this retrospective study, we used the data from National electronic system e-health which was performed in late 2014, wich gives us nearly precise data, and we made statistical analysis for diabetes in last 5 years (2015-2019). Results. In 2015 we have registered 103480 patients with DM, in 2016 108130 patients, in 2017 114408, in 2018 119999 and in 2019 124450 patients with DM. 95% of patients are with T2DM and 4, 1% with T1DM. According the data from State statistical office for population of Republic of Macedonia, the prevalence of T2DM for the years 2015-2019 is as follows: 5,66% in 2015, 6.13% In 2016, 6.55% I 2017, 7,06% in 2018 and 7,2% in 2019.   Conclusions. The number of registered  patients with diabetes in last 5 years has grown up for 20970 or 20%, in the last 5 years the number of patients with  type 2 diabetes has grown up for 18272 patients or 11%. The prevalence of T2DM has increased for 1.54%. Involvement of primary health care professionals has improved the early diagnosis of type 2 diabetes

Y-chromosome haplogroup architecture confers susceptibility to azoospermia factor c microrearrangements: a retrospective study

Aim To assess the association between azoospermia factor c microrearrangements and semen quality, and between Y-chromosome background with distinct azoospermia factor c microrearrangements and semen quality impairment. Methods This retrospective study, carried out in the Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov,” involved 486 men from different ethnic backgrounds referred for couple infertility from 2002- 2017: 338 were azoospermic/oligozoospermic and 148 were normozoospermic. The azoospermia factor c microrearrangements were analyzed with sequence tagged site and sequence family variant markers, quantitative fluorescent polymerase chain reaction, and multiplex ligation probe amplification analysis. The Y-haplogroups of all participants were determined with direct single nucleotide polymorphism typing and indirect prediction with short tandem repeat markers.Results Our participants had two types of microdeletions: gr/gr and b2/b3; three microduplications: b2/b4, gr/gr, and b2/b3; and one complex rearrangement gr/gr deletion + b2/b4 duplication. Impaired semen quality was not associated with microrearrangements, but b2/b4 and gr/ gr duplications were significantly associated with haplogroup R1a (P < 0.001 and P = 0.003, respectively) and b2/b3 deletions with haplogroup E (P = 0.005). There were significantly more b2/b4 duplication carriers in Albanians than in Macedonians with haplogroup R1a (P = 0.031). Conclusion Even though azoospermia factor c partial deletions/duplications and Y-haplogroups were not associated with impaired semen quality, specific deletions/ duplications were significantly associated with distinct haplogroups, implying that the Y chromosome background may confer susceptibility to azoospermia factor c microrearrangements

The Vibrational Stark Effect on the Doubly Degenerate &nu;19 Modes of the Benzene Guest Molecules in Hofmann Type Clathrates

An alternative mechanism is proposed for the observed splitting of the &nu;19 &gamma;(CH) mode of the benzene guest molecules in Hofmann type clathrates to the one presented previously.1 According to the proposed model, the splitting is due to the vibrational Stark effect. A simple quantum theoretical model for this effect is derived, based on the degenerate-case stationary perturbation theory, both with and without explicit inclusion of the vibrational angular momentum. The model allows estimation of the relative field strengths at the enclathration sites of the guest molecules in a series of structurally similar clathrates. The derived equations may be used for calculation of the local field strength as well, if particular anharmonic coupling constants for enclathrated species are available. The predictions of the proposed method are fully in line with the observed room temperature-low temperature trends for a particular clathrate, as well as with the trends in the series of isostructural clathrate compounds for which experimental data are available

Identification of the DNA methylation signature of Mowat-Wilson syndrome

Mowat-Wilson syndrome (MOWS) is a rare congenital disease caused by haploinsufficiency of ZEB2, encoding a transcription factor required for neurodevelopment. MOWS is characterized by intellectual disability, epilepsy, typical facial phenotype and other anomalies, such as short stature, Hirschsprung disease, brain and heart defects. Despite some recognizable features, MOWS rarity and phenotypic variability may complicate its diagnosis, particularly in the neonatal period. In order to define a novel diagnostic biomarker for MOWS, we determined the genome-wide DNA methylation profile of DNA samples from 29 individuals with confirmed clinical and molecular diagnosis. Through multidimensional scaling and hierarchical clustering analysis, we identified and validated a DNA methylation signature involving 296 differentially methylated probes as part of the broader MOWS DNA methylation profile. The prevalence of hypomethylated CpG sites agrees with the main role of ZEB2 as a transcriptional repressor, while differential methylation within the ZEB2 locus supports the previously proposed autoregulation ability. Correlation studies compared the MOWS cohort with 56 previously described DNA methylation profiles of other neurodevelopmental disorders, further validating the specificity of this biomarker. In conclusion, MOWS DNA methylation signature is highly sensitive and reproducible, providing a useful tool to facilitate diagnosis

Identification of the DNA methylation signature of Mowat-Wilson syndrome

Mowat-Wilson syndrome (MOWS) is a rare congenital disease caused by haploinsufficiency of ZEB2, encoding a transcription factor required for neurodevelopment. MOWS is characterized by intellectual disability, epilepsy, typical facial phenotype and other anomalies, such as short stature, Hirschsprung disease, brain and heart defects. Despite some recognizable features, MOWS rarity and phenotypic variability may complicate its diagnosis, particularly in the neonatal period. In order to define a novel diagnostic biomarker for MOWS, we determined the genome-wide DNA methylation profile of DNA samples from 29 individuals with confirmed clinical and molecular diagnosis. Through multidimensional scaling and hierarchical clustering analysis, we identified and validated a DNA methylation signature involving 296 differentially methylated probes as part of the broader MOWS DNA methylation profile. The prevalence of hypomethylated CpG sites agrees with the main role of ZEB2 as a transcriptional repressor, while differential methylation within the ZEB2 locus supports the previously proposed autoregulation ability. Correlation studies compared the MOWS cohort with 56 previously described DNA methylation profiles of other neurodevelopmental disorders, further validating the specificity of this biomarker. In conclusion, MOWS DNA methylation signature is highly sensitive and reproducible, providing a useful tool to facilitate diagnosis

ВажноÑÑ‚ на 6 минутниот теÑÑ‚ на одење во дијагноÑтика на ретка метаболна миопатија – приказ на Ñлучај на карнитин палмитоил транÑфераза 2 дефицит

Diagnosis of rare inherited neuromuscular disorders is sometimes delayed due to variations in time of onset, different clinical appearance and limited diagnostic possibilities. The management of patients  starts  with neurological examination, followed by  specific laboratory tests  and neurophysiologic assessment. In the  era of molecular medicine, molecular biology tools are useful in avoiding some of the invasive investigations such as muscle biopsy. We present a boy with a mild form of metabolic myopathy due to carnitine  palmitoyltransferase  2 deficiency diagnosed upon timed functional assessment. A child had delayed developmental milestones, associated with fatigue and muscle pain during exercising and longer walks. There were no episodes of myoglobinuiria during exercise or during febrile illnesses. Neurological examination reveled proximal muscle weakness. Serum creatine kinase (CK) and serum lactate were above normal limits. Serum acylcarnitine profile was normal. Short timed functional tests such as 10 meters  walk/run test  showed normal results. Nord Star Ambulatory Assessment showed difficulties in balance and jumping. Diagnosis of myopathy was suspected after performance of 6-minute walk test, when the passed distance was 327 meters with slowing and fatigue. EMG and echocardiography were within normal range. Diagnosis was established by sequencing  of the CPT II gene which revealed   c.338C&gt;T (p.Ser113Leu) mutation in homozygous form as characteristic CPT II deficiency profile.Дијагнозата на ретките невромуÑкулни заболувања е понекогаш пролонгирана заради различното вре- ме на почеток на Ñимптомите, различната клиничка Ñлика и ограничените дијагноÑтички можноÑти. Обработката на пациентот започнува Ñо невролошки преглед, по што Ñледат Ñпецифични лаборато- риÑки теÑтови и неврофизиолошки иÑпитувања. Во ера на молекуларната медицина, генетÑката анали- за овозможува да Ñе избегнат некои од инвазивните иÑпитувања, како на пример муÑкулната биопÑија. Прикажуваме момче Ñо блага форма на метаболичка миопатија Ñо карнитин палмитоил транÑфераза 2 (CPT II) дефицит, која е дијагноÑтицирана врз оÑнова на временÑка функционална проценка. Детето имало забавен моторен развој, Ñо замор и муÑкулна болка во тек на вежбање или подолго одење. Ðема- ло епизоди на миоглобинурија во тек на вежбање или во тек на фебрилни болеÑти. Ðевролошкиот пре- глед покажа прокÑимална муÑкулна ÑлабоÑÑ‚. СерумÑката креатин киназа и ÑерумÑкото ниво на лакта- ти беа над нормалните граници. СерумÑкиот профил на ацил карнитини беше нормален. Кратките функционални теÑтови како 10 метри одење/трчање покажаа уредни резултати. Nord Star Ambulatory Assessment  – теÑтирањето покажа потешкотии во рамнотежата и при Ñкокање. Сомнение за вродена миопатија Ñе поÑтави по изведување на подолготраен функционален теÑÑ‚ – 6-минутниот теÑÑ‚ на одење кога поминатата  Ð´Ð¸Ñтанца беше 327 метри Ñо уÑпорување и замор. Електроневромиографијата и ехо- кардиографијата кај детето покажаа нормални наоди. Дијагнозата беше потврдена Ñо Ñеквенциони- рање на CPT II генот Ñо региÑтрирање на c.338C&gt;T (p.Ser113Leu) мутација  Ð²Ð¾ хомозиготна форма која е карактериÑтична за CPT II дефицит